CLRB
Cellectar Biosciences, Inc.
NASDAQ · USHealthcareBiotechnology
$2.52+0.40%
Price as of Jul 20, 2026
CLRB growth
Cellectar Biosciences, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- +54.9%
- EBIT
- +51.6%
- EPS
- +58.8%
- Free cash flow
- +57.4%
- Operating cash flow
- +57.4%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +73.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +51.2%
- EBIT
- +55.6%
- Net income
- +51.1%
- EPS
- +77.1%
- Free cash flow
- +51.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.